MarketCap
Facebook
X
Telegram
Eargo Revenue | EAR
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Eargo
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 37.2 M | 32.1 M | 69.2 M | 32.8 M | 23.2 M | 6.62 M | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 69.2 M | 6.62 M | 33.5 M |
Quarterly Revenue Eargo
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 8.27 M | 8.11 M | 11.8 M | - | 7.91 M | 7.25 M | 9.18 M | - | - | 22.9 M | 22 M | - | 18.2 M | 15.9 M | 12.7 M | - | 7.73 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 22.9 M | 7.25 M | 12.7 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Medical devices industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Orthofix Medical
OFIX
|
822 M | $ 9.81 | -1.8 % | $ 388 M |  Curacao |
 |
TransMedics Group
TMDX
|
605 M | $ 70.74 | -1.83 % | $ 2.4 B |  USA |
 |
Abbott Laboratories
ABT
|
44.3 B | $ 103.7 | 1.17 % | $ 181 B | USA |
 |
Electromed
ELMD
|
73.8 M | $ 26.37 | -1.86 % | $ 218 M | USA |
 |
Align Technology
ALGN
|
4.03 B | $ 154.51 | -0.64 % | $ 11.2 B | USA |
 |
InMode Ltd.
INMD
|
370 M | $ 13.97 | -0.57 % | $ 903 M |  Israel |
 |
Nevro Corp.
NVRO
|
409 M | - | - | $ 217 M | USA |
 |
Inspire Medical Systems
INSP
|
912 M | $ 71.11 | -2.13 % | $ 2.09 B | USA |
 |
Apyx Medical Corporation
APYX
|
52.8 M | $ 2.37 | -1.66 % | $ 97.4 M | USA |
 |
IRIDEX Corporation
IRIX
|
52.7 M | $ 0.75 | -2.18 % | $ 12.7 M | USA |
 |
IRadimed Corporation
IRMD
|
83.8 M | $ 85.82 | -2.08 % | $ 1.09 B | USA |
 |
Accuray Incorporated
ARAY
|
402 M | $ 0.13 | -2.91 % | $ 15.9 M | USA |
 |
Aethlon Medical
AEMD
|
574 K | $ 5.05 | -2.7 % | $ 3.4 M | USA |
 |
Venus Concept
VERO
|
64.8 M | - | - | $ 726 K | USA |
 |
LENSAR
LNSR
|
58.4 M | $ 6.07 | 0.83 % | $ 72.6 M | USA |
 |
Alphatec Holdings
ATEC
|
764 M | $ 11.11 | -2.2 % | $ 1.67 B | USA |
 |
Medtronic PLC
MDT
|
36.4 B | $ 95.41 | -1.18 % | $ 122 B | USA |
 |
Sientra
SIEN
|
25.1 M | - | -16.59 % | $ 10.3 M | USA |
 |
AxoGen
AXGN
|
225 M | $ 38.06 | 3.76 % | $ 1.75 B | USA |
 |
Silk Road Medical, Inc
SILK
|
177 M | - | - | $ 1.07 B | USA |
 |
Myomo
MYO
|
40.9 M | $ 1.21 | -0.82 % | $ 50.6 M | USA |
 |
Surgalign Holdings
SRGA
|
82 M | - | -32.98 % | $ 1.68 M | USA |
 |
ShockWave Medical
SWAV
|
730 M | - | - | $ 12.3 B | USA |
 |
Bio-Rad Laboratories
BIO
|
2.58 B | $ 369.95 | 1.68 % | $ 10.1 B | USA |
 |
Abiomed
ABMD
|
1.03 B | - | - | $ 17.2 B | USA |
 |
Titan Medical
TMDI
|
20.1 M | - | -26.32 % | $ 19.6 M |  Canada |
 |
Natus Medical Incorporated
NTUS
|
473 M | - | 1.94 % | $ 1.05 B | USA |
 |
Cardiovascular Systems
CSII
|
236 M | - | 0.15 % | $ 844 M | USA |
 |
Outset Medical
OM
|
119 M | $ 4.1 | -1.68 % | $ 62.4 K | USA |
 |
Bruker Corporation
BRKR
|
3.44 B | $ 57.59 | 0.49 % | $ 8.74 B | USA |
 |
Boston Scientific Corporation
BSX
|
20.1 B | $ 45.69 | -0.7 % | $ 67.6 B | USA |
 |
Inari Medical
NARI
|
494 M | - | - | $ 4.23 B | USA |
 |
Allied Healthcare Products
AHPI
|
6.02 M | - | 3.58 % | $ 2.21 M | USA |
 |
PAVmed
PAVM
|
71 K | $ 2.17 | 5.85 % | $ 1.45 M | USA |
 |
Insulet Corporation
PODD
|
2.71 B | $ 149.01 | 0.6 % | $ 10.5 B | USA |
 |
Profound Medical Corp.
PROF
|
16.1 M | $ 5.56 | -3.47 % | $ 168 M | Canada |
 |
AVITA Medical
RCEL
|
71.6 M | $ 15.51 | 0.58 % | $ 432 M |  Australia |
 |
Avinger
AVGR
|
7.65 M | - | -20.74 % | $ 369 K | USA |
 |
Apollo Endosurgery
APEN
|
76.9 M | - | - | $ 475 M | USA |
 |
NuVasive
NUVA
|
1.2 B | - | - | $ 2.07 B | USA |
 |
Butterfly Network
BFLY
|
97.6 M | $ 6.76 | -0.81 % | $ 1.67 B | USA |
 |
ClearPoint Neuro
CLPT
|
37 M | $ 9.14 | -1.19 % | $ 259 M | USA |
 |
Sintx Technologies
SINT
|
1.02 M | $ 1.58 | -3.66 % | $ 4.38 M | USA |
 |
CONMED Corporation
CNMD
|
1.37 B | $ 49.25 | -0.11 % | $ 1.53 B | USA |
 |
Smith & Nephew plc
SNN
|
4.56 B | $ 30.83 | -0.11 % | $ 26.7 B |  Britain |
 |
Sensus Healthcare
SRTS
|
27.5 M | $ 2.95 | 1.55 % | $ 48.2 M | USA |
 |
Cytosorbents Corporation
CTSO
|
37.1 M | $ 5.27 | -12.31 % | $ 328 M | USA |
 |
Axonics Modulation Technologies
AXNX
|
366 M | - | - | $ 3.31 B | USA |
 |
ThermoGenesis Holdings
THMO
|
9.44 M | - | -25.84 % | $ 171 K | USA |